Cartesian Therapeutics to Participate in Upcoming Investor Conferences
Cartesian Therapeutics (NASDAQ: RNAC), a clinical-stage biotech company focusing on mRNA cell therapy for autoimmune diseases, has announced its participation in two upcoming investor conferences in September 2024:
1. H.C. Wainwright 26th Annual Global Investment Conference on September 9 at 2:30 p.m. ET in New York, NY
2. Cantor Global Healthcare Conference on September 17 at 9:45 a.m. ET in New York, NY
The company's management will participate in fireside chats at both events. Live webcasts of these discussions will be available on the Events section of Cartesian Therapeutics' website, with archived replays accessible for a time.
Cartesian Therapeutics (NASDAQ: RNAC), un'azienda biotecnologica in fase clinica specializzata in terapia cellulare mRNA per le malattie autoimmuni, ha annunciato la sua partecipazione a due prossimi conferenze per investitori a settembre 2024:
1. H.C. Wainwright 26° Annual Global Investment Conference il 9 settembre alle 14:30 ET a New York, NY
2. Cantor Global Healthcare Conference il 17 settembre alle 9:45 ET a New York, NY
La direzione dell'azienda parteciperà a discussioni informali in entrambi gli eventi. I webcast dal vivo di questi interventi saranno disponibili nella sezione Eventi del sito web di Cartesian Therapeutics, con repliche archiviate accessibili per un periodo limitato.
Cartesian Therapeutics (NASDAQ: RNAC), una empresa de biotecnología en etapa clínica que se enfoca en terapia celular de mRNA para enfermedades autoinmunes, ha anunciado su participación en dos próximas conferencias para inversores en septiembre de 2024:
1. H.C. Wainwright 26ª Conferencia Anual Global de Inversión el 9 de septiembre a las 2:30 p.m. ET en Nueva York, NY
2. Conferencia Global de Atención Médica de Cantor el 17 de septiembre a las 9:45 a.m. ET en Nueva York, NY
La dirección de la empresa participará en charlas informales en ambos eventos. Los webcasts en vivo de estas discusiones estarán disponibles en la sección de Eventos del sitio web de Cartesian Therapeutics, con repeticiones archivadas accesibles por un tiempo limitado.
Cartesian Therapeutics (NASDAQ: RNAC), 자가면역 질환을 위한 mRNA 세포 치료에 중점을 둔 임상 단계의 생명공학 회사가 2024년 9월에 열리는 두 개의 투자자 회의에 참가할 예정이라고 발표했습니다:
1. H.C. Wainwright 제26회 글로벌 투자 컨퍼런스가 9월 9일 오후 2시 30분 ET에 뉴욕에서 개최됩니다.
2. 캔토 글로벌 헬스케어 컨퍼런스가 9월 17일 오전 9시 45분 ET에 뉴욕에서 열립니다.
회사의 경영진이 두 행사에서 대화형 세션에 참여할 것입니다. 이 논의의 생중계는 Cartesian Therapeutics 웹사이트의 이벤트 섹션에서 제공되며, 아카이브된 재생본도 일정 기간 동안 접근할 수 있습니다.
Cartesian Therapeutics (NASDAQ: RNAC), une société biopharmaceutique en phase clinique axée sur la thérapie cellulaire mRNA pour les maladies auto-immunes, a annoncé sa participation à deux prochaines conférences pour investisseurs en septembre 2024 :
1. 26ème Conférence Annuelle Mondiale d'Investissement H.C. Wainwright le 9 septembre à 14h30 ET à New York, NY
2. Conférence Mondiale sur les Soins de Santé de Cantor le 17 septembre à 9h45 ET à New York, NY
La direction de l'entreprise participera à des discussions informelles lors des deux événements. Des diffusions en direct de ces échanges seront disponibles dans la section Événements du site web de Cartesian Therapeutics, avec des rediffusions archivées accessibles pour une durée limitée.
Cartesian Therapeutics (NASDAQ: RNAC), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf mRNA-Zelltherapie für Autoimmunerkrankungen konzentriert, hat seine Teilnahme an zwei bevorstehenden Investorenkonferenzen im September 2024 angekündigt:
1. H.C. Wainwright 26. jährliche globale Investorenkonferenz am 9. September um 14:30 Uhr ET in New York, NY
2. Cantor Global Healthcare Conference am 17. September um 9:45 Uhr ET in New York, NY
Die Unternehmensleitung wird an informellen Gesprächen bei beiden Veranstaltungen teilnehmen. Live-Webcasts dieser Diskussionen sind auf der Veranstaltungsseite der Website von Cartesian Therapeutics verfügbar, und archivierte Wiederholungen sind für eine Zeit lang zugänglich.
- None.
- None.
GAITHERSBURG, Md., Aug. 26, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in September:
- A fireside chat at the H.C. Wainwright 26th Annual Global Investment Conference at 2:30 p.m. ET on Monday, September 9, 2024 in New York, NY
- A fireside chat at the Cantor Global Healthcare Conference at 9:45 a.m. ET on Tuesday, September 17, 2024 in New York, NY
A live webcast of the fireside chats are expected to be accessible in the Events section of the Company’s website at www.cartesiantherapeutics.com, where an archived replay of the events will also be available for a limited time.
About Cartesian Therapeutics
Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a potential first-in-class mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis and Phase 2 development for systematic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X, formerly known as Twitter.
Contact Information:
Investor Relations:
Argot Partners
cartesian@argotpartners.com
Media:
David Rosen
Argot Partners
david.rosen@argotpartners.com
FAQ
When is Cartesian Therapeutics (RNAC) participating in the H.C. Wainwright Global Investment Conference?
What time is Cartesian Therapeutics' (RNAC) fireside chat at the Cantor Global Healthcare Conference?
Where can investors access the webcasts of Cartesian Therapeutics' (RNAC) investor conference presentations?
What is the main focus of Cartesian Therapeutics (RNAC) as a biotechnology company?
